Metsera responds to Pfizer litigation amid competing acquisition bids
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Metsera Issues Statement in Response to Litigation
November 3, 2025 11:02 AM ESTNEW YORK, Nov. 3, 2025 /PRNewswire/ --Â Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:
"Pfizer is trying to litigate its way to buying Metsera for a lower price than Novo Nordisk. Metsera's Board of Directors will continue to stand firm on behalf of shareholders and patients. Pfizer's litigation arguments are nonsense, and Metsera will address them in court."
... More
